Figure 4.
Challenges for CAR T-cell Immunotherapy in Solid Tumors (1). heterogeneous expression of tumor-associated antigens (TAA), leading to the growth of antigen-negative tumor variants (2); inefficient trafficking of CAR T cells at tumor sites (3); a poorly metabolized tumor microenvironment, including immunosuppressive molecules and cells are present, which can lead to CAR T-cell exhaustion.
